Law Offices of Thomas J. Lamb

  • About Firm
  • Practice Areas
  • Free Case Evaluation
  • Quick Contact Form
  • Frequently Asked Questions
  • Attorney Tom Lamb

NAION Ozempic Side-Effect Warning: Novo Nordisk Failure

March 6, 2026 By Law Offices of Thomas J. Lamb, P.A.

We have written about the NAION Ozempic side-effect warning issue several times over the past year-and-a-half, and have repeatedly pointed out that non-arteritic anterior ischemic optic neuropathy, or NAION, is linked to semaglutide.  Moreover, we noted that semaglutide is the active ingredient in the currently available Novo Nordisk semaglutide medicines: Ozempic injection, Wegovy injection, Wegovy tablet, and Rybelsus tablet. Furthermore, we have asserted that all Novo Nordisk semaglutide medicines should carry an NAION side-effect warning.

As of late January 2026, however, there is still no NAION side-effect warning for Ozempic and Rybelsus. See “Revised: 1/2026” Prescribing Information document for “RYBELSUS and OZEMPIC tablets” [PDF document]. And there is no NAION side-effect warning for Wegovy.

Here are two earlier articles from our Drug Injury Watch blog that provide support for our assertion that there should be an NAION Ozempic side-effect warning in that January 2026 drug label for the new pill version of Ozempic, soon to be available, as well as the current drug label for the already available, and popular, Ozempic injection:

  • “Risk of NAION With Semaglutide Medicines is 2 Times Higher Than SGLT2i Diabetes Drugs” (2/13/2026)
  • “Wegovy and Ozempic Increase NAION Risk, an Eye Side Effect That Can Result in Blindness” (10/22/2025)

NAION Ozempic Side-Effect Warning Lawsuits

The failure by Novo Nordisk to have an NAION side-effect warning available for doctors who prescribe Ozempic, as well as the people who use Ozempic, is the basis for drug injury lawsuits that have been filed against this pharmaceutical company on behalf of people diagnosed with NAION. These Ozempic lawsuits are product liability cases based in part on a failure-to-warn allegation.

A person diagnosed with NAION while using Ozempic, Wegovy, or Rybelsus — the Novo Nordisk semaglutide medicines — may want to submit an Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form online. It is free, confidential, and there is no obligation.

In the alternative, if you have a possible Wegovy, Rybelsus, or Ozempic NAION lawsuit that you want evaluated by attorney Tom Lamb, you can send an email to TJL@LambLawOffice.com or call 910-256-2971.


Ozempic / Wegovy / Rybelsus

Free Case Evaluation

Strictly Confidential, No Obligation

Filed Under: Unsafe Drugs Tagged With: drug injury, drug injury lawsuits, Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), Ozempic, Rybelsus, semaglutide-containing drugs, Wegovy

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call 910-256-2971 to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

910-256-2971

Main Navigation Menu

  • About Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

DrugInjuryLaw.com

DrugInjuryWatch.com

Asbestos-Mesothelioma.com

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971
TJL@LambLawOffice.com

  • Home
  • Disclaimer and Copyright Notices
  • Sitemap

Copyright © 2026 · Law Offices of Thomas J. Lamb, P.A.